EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
The European Medicines Agency (EMA) has offered a positive opinion to Novo Nordisk, which should pave the way for the…
The European Medicines Agency (EMA) has offered a positive opinion to Novo Nordisk, which should pave the way for the…
Rona Therapeutics has secured $35m in its Series A+ financing round to advance its metabolic small interfering RNA (siRNA) pipeline…
German contract development and manufacturing organisation (CDMO) Corden Pharma announced a €900m ($980m) investment to expand its diabetes drug manufacturing…
The US Food and Drug Administration (FDA) has rejected the biologics licence application (BLA) for Novo Nordisk’s once-weekly insulin icodec…
On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, for $35.1m. Avexitide…
The glucagon-like peptide 1 (GLP-1) receptor agonists have emerged as blockbuster drugs and have raked in billions in sales. However,…
Altimmune has taken another step to claim its share in the growing obesity drug market with new data showing its…
The World Health Organization (WHO) has issued an alert on falsified versions of Novo Nordisk’s blockbuster type 2 diabetes drug…
England’s National Health Service (NHS) has reported an 18% increase in the number of people with non-diabetic hyperglycaemia – also…
Flagship Pioneering and ProFound Therapeutics have entered a partnership to develop new therapeutics for the treatment of obesity. The collaboration…